Tohoku University Technology: Prognostic Marker for Pancreatic Cancer: T18-068
The regulation of gene X expression by BACH1 is a key network involved in the epithelial-mesenchymal transition of pancreatic cancer.
Pancreatic cancer has long been positioned as an unmet medical need due to the lack of effective treatments and early diagnostic markers. This invention is supported by the confirmation that the transcription factor BACH1 suppresses the expression of FOXA1, which enhances the epithelial-mesenchymal transition of tumor cells. It relates to the use of BACH1 and FOXA1 as prognostic markers for pancreatic cancer. In pancreatic cancer cell lines with BACH1 knockdown, the mRNA levels of FOXA1 increased, while in cell lines with BACH1 overexpression, the expression levels of FOXA1 decreased (Figure 1). This confirms that FOXA1 is regulated by the expression of BACH1. Additionally, pancreatic cancer cell lines with BACH1 knockdown exhibited significantly reduced migratory and invasive abilities compared to controls (Figure 2). Furthermore, an analysis of the prognosis of pancreatic cancer patients revealed that those classified as BACH1 Low/FOXA1 High had the best prognosis, while those classified as BACH1 High/FOXA1 Low had the worst prognosis (Figure 3). This trend may be explained by the relationship with the metastatic/invasive potential of pancreatic cancer cells controlled by the BACH1-FOXA1 network.
- Company：Tohoku Techno Arch Co., Ltd.
- Price：Other
